Background—Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal
adenomas but have been associated with increased cardiovascular risk. Methods and …

Background Overexpression of cyclooxygenase 2 (COX-2) has been associated with
colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition …

Background Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny
because of reports suggesting an increased cardiovascular risk associated with their use …

Background Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the
number of colorectal adenomas in animals and patients with familial adenomatous …

Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of
the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention …

Abstract Background Cyclooxygenase (COX)-2 inhibitors such as celecoxib were designed
to preserve anti-inflammatory activity without inhibiting COX-1. Downregulation of COX-2 …

Background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an
increased risk of thrombotic events, but only limited long-term data have been available for …

Background Selective inhibition of cyclo-oxygenase-2 has been associated with an
increased risk of cardiovascular events in several clinical trials. The Adenomatous Polyp …

OBJECTIVES: Subjects in the Prevention of Colorectal Sporadic Adenomatous Polyps
(PreSAP) trial (PRESAP/NCT00141193/www. clinicaltrials. gov) were studied to determine …

Approximately six years after the cyclooxygenase-2 (COX-2) inhibitors were approved for
use in the United States, the results of three randomized, placebo-controlled trials provide …